|1.||Janjic, Nebojsa: 2 articles (05/2009 - 05/2009)|
|2.||Young, Casey L: 2 articles (05/2009 - 05/2009)|
|3.||Critchley, Ian A: 2 articles (05/2009 - 05/2009)|
|4.||Ochsner, Urs A: 2 articles (05/2009 - 05/2009)|
|5.||Goldstein, Ellie J C: 1 article (05/2009)|
|6.||Bullard, James M: 1 article (05/2009)|
|7.||Green, Louis S: 1 article (05/2009)|
|8.||Price, Melissa: 1 article (05/2009)|
|9.||Guiles, Joseph W: 1 article (05/2009)|
|10.||Stone, Kimberley Clawson: 1 article (05/2009)|
05/01/2009 - "Spectrum of activity and mode of action of REP3123, a new antibiotic to treat Clostridium difficile infections."
05/01/2009 - "Inhibitory effect of REP3123 on toxin and spore formation in Clostridium difficile, and in vivo efficacy in a hamster gastrointestinal infection model."
05/01/2009 - "The aim of this study was to characterize the antimicrobial profile of REP3123, a novel inhibitor of methionyl-tRNA synthetase (MetRS) in development for the treatment of Clostridium difficile infection. "
05/01/2009 - "REP3123 is a fully synthetic methionyl-tRNA synthetase inhibitor in pre-clinical development as a novel agent to treat Clostridium difficile infection (CDI). "
05/01/2009 - "difficile infection and 223 other intestinal normal flora anaerobes were tested for their susceptibility to REP3123 and four or five comparator agents by the agar dilution method using supplemented Brucella agar with 5% laked sheep blood. "